Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02123758 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
57
Enrollment target
7
Study locations

NCT02123758 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms that is active but no longer recruiting, run by Aragon Pharmaceuticals. The registered enrollment target is 57 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (71% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02123758, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, is active but no longer recruiting, sponsored by Aragon Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
57 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Prostatic Neoplasms

Interventions

  • DRUG Prednisone
  • DRUG Abiraterone Acetate
  • DRUG JNJ-56021927

Study Locations (7)

California

  • - Los Angeles
  • - San Francisco

Other

  • - Rotterdam
  • - Sutton

Texas

  • - Houston

British Columbia

  • - Vancouver

Quebec

  • - Montreal

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2014-07-09
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

Aragon Pharmaceuticals

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02123758

The ClinicalTrials.gov registry entry for NCT02123758 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.

NCT02123758 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Other, Texas.

Frequently Asked Questions

What is clinical trial NCT02123758 about?

NCT02123758 is a clinical study titled "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potential...

What is the current status of trial NCT02123758?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2014-07-09. Estimated completion is 2027-12-31.

What conditions does trial NCT02123758 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms.

What interventions are being tested in trial NCT02123758?

The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG), JNJ-56021927 (DRUG).

Who is sponsoring clinical trial NCT02123758?

This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02123758 being conducted?

This trial has 7 study locations across California, Texas, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Prostatic Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.